Healthcare & Pharmaceutical Market Research in Sweden

BioNixus is a leading healthcare market research company in Sweden, delivering ethics-authority-compliant HCP surveys, KOL mapping, and payer landscape research aligned with Läkemedelsverket, TLV, and regional procurement requirements. BioNixus combines primary research depth with physician access across major Swedish university hospitals and specialist networks.

A healthcare market research company in Sweden designs and executes studies covering physician prescribing behaviour, regional payer and reimbursement access dynamics, patient journeys, KOL influence mapping, and competitive landscape intelligence — for pharmaceutical, biotech, and medical device companies launching or growing in the Swedish market.

Sweden operates a universal, tax-funded welfare-state healthcare system delivered and funded by 21 regions (landsting/regioner). Läkemedelsverket (the Swedish Medical Products Agency) grants marketing authorisation, but commercial outcomes depend on TLV (the Dental and Pharmaceutical Benefits Agency) value-based health technology assessment and reimbursement pricing decisions, as well as regional procurement and formulary practices. The NT Council (Nya Terapier) coordinates national introduction and joint recommendations for new specialist and high-cost drugs across the regions, adding a further layer of coordinated decision-making that is distinct from most other European markets.

BioNixus covers oncology, immunology and biologics (including regional biosimilar switching practices), cardiovascular, diabetes and metabolic (including GLP-1), rare disease, respiratory, infectious disease, neurology, medical devices, and consumer health across the Swedish market.

Yes. BioNixus maintains physician and specialist networks across major Swedish academic medical centres including Karolinska University Hospital, Uppsala University Hospital, and Skåne University Hospital (Lund). For scarce specialties such as oncology or rare disease, we recruit through university hospital networks affiliated with Karolinska Institutet, Uppsala University, and Lund University, as well as rare disease specialist directories.

Focused HCP surveys complete in 3–4 weeks. Full mixed-method programmes including regional payer depth interviews and advisory board modules typically run 6–10 weeks depending on therapy area, ethics review requirements, and respondent scarcity. Oncology and rare disease KOL programmes with multi-centre recruitment across regions may require extended planning timelines.

Yes. BioNixus designs and executes Swedish patient research in compliance with GDPR data privacy standards and Swedish Ethical Review Authority (Etikprövningsmyndigheten) research ethics requirements. All patient and caregiver research involves documented informed consent, de-identified reporting, and secure data handling consistent with EU and Swedish privacy legislation.

Yes. Swedish modules can run with comparable cells in the UK, EU5 (Germany, France, Italy, Spain), the USA, Canada, Saudi Arabia, and UAE — using consistent instruments for global portfolio committees managing multi-market access strategy from one research partner.